EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Blood-based biomarkers in Alzheimer’s and Parkinson’s disease: From molecular pathology to therapeutic potential

Priya, Radhika Mittal, Jyotirmoy Banerjee, Aparna Dixit

International Review of Neurobiology · 2026

DOI: 10.1016/bs.irn.2026.02.006 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Review of Neurobiology, 2026. Verfasst von Priya und 3 weiteren Autor:innen. Beteiligte Einrichtung: Dr. B R Ambedkar Centre for Biomedical Research, University of Delhi, Delhi, India. Hauptthemen laut MEDLINE: Parkinson Disease, Biomarkers, Alzheimer Disease, alpha-Synuclein. Die Arbeit nennt 177 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's (AD) and Parkinson's disease (PD) represent a major class of neurodegenerative disorders characterized by different proteinopathies with amyloid-β plaques and tau tangles in AD, while α-synuclein containing Lewy bodies in PD, specific molecular signatures. Alongside this central mechanism, they share pathological cascades including axonal degeneration, synaptic dysfunction, glial activation and neuroinflammation. The emergence of blood-based biomarkers, represents a paradigm shift in the field of diagnosis and therapeutics by addressing these core pathological mechanism of central nervous system. This chapter highlights a overview of blood-based biomarkers emerging in the field of AD and PD, exploring the clinical utility of core pathology markers (Aβ42/40, p-tau species, and α-synuclein), alongside other neurodegenerative markers such as neurofilament light chain and glial activation markers like GFAP. Beyond the diagnosis, we emphasize on the potential role of blood-based biomarkers as a surrogate and pharmacodynamic endpoint in disease modifying clinical trial development, facilitating dose optimization and target engagement. Future prospects empathize on the use of multimodal approach integration, trajectory modeling and novel target discovery. Collectively, these blood-based biomarkers enable transition of neurodegenerative disorders treatment from symptom-based classification to towards a mechanism targeted therapeutic framework.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseBiomarkersAlzheimer Diseasealpha-SynucleinHumansAnimalsAmyloid beta-PeptidesPathology, Moleculartau Proteins

Stichwörter der Autor:innen

Alpha-synuclein blood based biomarkerAlzheimer’s diseaseAmyloid-betaParkinson’s disease

Substanzen

Biomarkersalpha-SynucleinAmyloid beta-Peptidestau Proteins

Autor:innen und Institutionen

  • Dr. B R Ambedkar Centre for Biomedical Research, University of Delhi, Delhi, India.
  • Department of Biophysics, AIIMS, New Delhi, India.
  • Dr. B R Ambedkar Centre for Biomedical Research, University of Delhi, Delhi, India. Electronic address: aparnabanerjeedixit@gmail.com.

Zitieren

APA

Priya, Mittal, R., Banerjee, J., & Dixit, A. (2026). Blood-based biomarkers in Alzheimer’s and Parkinson’s disease: From molecular pathology to therapeutic potential. International Review of Neurobiology. https://doi.org/10.1016/bs.irn.2026.02.006

Vancouver

Priya, Mittal R, Banerjee J, Dixit A. Blood-based biomarkers in Alzheimer’s and Parkinson’s disease: From molecular pathology to therapeutic potential. International Review of Neurobiology. 2026. doi:10.1016/bs.irn.2026.02.006

BibTeX
@article{Priya2026,
  author = {Priya and Mittal, Radhika and Banerjee, Jyotirmoy and Dixit, Aparna},
  title = {Blood-based biomarkers in Alzheimer’s and Parkinson’s disease: From molecular pathology to therapeutic potential},
  journal = {International Review of Neurobiology},
  year = {2026},
  doi = {10.1016/bs.irn.2026.02.006}
}
Kostenlos starten →